deoxyglucose has been researched along with Parkinson Disease, Secondary in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (55.56) | 18.7374 |
| 1990's | 7 (38.89) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lang, AE | 1 |
| Calne, DB; Doudet, D; Hewitt, KA; Nugent, R; Olanow, W; Pate, BD; Perl, DP; Shinotoh, H; Snow, BJ | 1 |
| Buchholz, J; Carlson, JD; Iacono, RP; Maeda, G; Pearlstein, RD | 1 |
| Duan, W; Mattson, MP | 1 |
| Albin, RL; Kearney, JA | 1 |
| Cederbaum, J; Dhawan, V; Eidelberg, D; Fahn, S; Ginos, JZ; Greene, P; Moeller, JR; Powers, JM; Sidtis, JJ; Strother, SC | 1 |
| Boyce, S; Clarke, CA; Crossman, AR; Robertson, RG; Sambrook, MA | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Luquin, R; Mitchell, IJ; Robertson, RG; Sambrook, MA | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Mitchell, IJ; Peggs, D; Robertson, RG; Sambrook, MA | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Robertson, RG; Sambrook, MA | 1 |
| Adam, MJ; Calne, DB; Grierson, JR; Martin, WR; Palmer, M; Pate, BD; Ruth, TJ; Stoessl, AJ | 1 |
| Cross, AJ; Crossman, AR; Mitchell, IJ; Sambrook, MA | 1 |
| Hanson, WR; Metter, EJ | 1 |
| Alexander, GM; Schwartzman, RJ | 2 |
| Burns, RS; Crane, AM; Kopin, IJ; Palombo, E; Porrino, LJ; Sokoloff, L | 1 |
| Crossman, AR; Mitchell, IJ; Sambrook, MA | 1 |
| Snyder, AM; Stricker, EM; Zigmond, MJ | 1 |
2 review(s) available for deoxyglucose and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome.
Topics: Antiparkinson Agents; Blood Glucose; Carbidopa; Contrast Media; Deoxyglucose; Dihydroxyphenylalanine; Dominance, Cerebral; Drug Combinations; Female; Fluorodeoxyglucose F18; Functional Laterality; Hemiplegia; Humans; Levodopa; Middle Aged; Muscle Hypotonia; Muscular Atrophy; Neurologic Examination; Parkinson Disease, Secondary; Physical Exertion; Substantia Nigra; Tomography, Emission-Computed | 1995 |
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Deoxyglucose; Haplorhini; Humans; Levodopa; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Spiperone | 1987 |
16 other study(ies) available for deoxyglucose and Parkinson Disease, Secondary
| Article | Year |
|---|---|
MRI and PET studies of manganese-intoxicated monkeys.
Topics: Animals; Carbidopa; Corpus Striatum; Deoxyglucose; Drug Therapy, Combination; Dystonia; Fluorodeoxyglucose F18; Globus Pallidus; Glucose; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Male; Manganese Poisoning; Parkinson Disease, Secondary; Raclopride; Salicylamides; Substantia Nigra; Tomography, Emission-Computed | 1995 |
Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antimetabolites; Basal Ganglia Diseases; Cerebral Cortex; Deoxyglucose; Disease Models, Animal; Dopamine; Energy Metabolism; Glucose; Male; Oxidopamine; Parkinson Disease, Secondary; Pons; Rats; Rats, Sprague-Dawley; Sympatholytics | 1999 |
Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease.
Topics: Animals; Antimetabolites; Apoptosis; Behavior, Animal; Carrier Proteins; Corpus Striatum; Deoxyglucose; Disease Models, Animal; Dopamine; Dopamine Agents; Endoplasmic Reticulum Chaperone BiP; Energy Intake; Ferrous Compounds; Heat-Shock Proteins; Heat-Shock Response; HSP70 Heat-Shock Proteins; Male; Mice; Mice, Inbred C57BL; Mitochondria; Molecular Chaperones; MPTP Poisoning; Nerve Degeneration; Neurons; Parkinson Disease, Secondary; Reactive Oxygen Species; Rotenone; Substantia Nigra; Uncoupling Agents | 1999 |
Intrasubthalamic nucleus metabotropic glutamate receptor activation: a behavioral, Fos immunohistochemical and [14C]2-deoxyglucose autoradiographic study.
Topics: 4-Aminopyridine; Amino Acids, Dicarboxylic; Animals; Antimetabolites; Autoradiography; Behavior, Animal; Carbon Radioisotopes; Corpus Striatum; Deoxyglucose; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Glucose; Immunohistochemistry; Male; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Rotation; Substantia Nigra; Subthalamic Nucleus | 2000 |
The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography.
Topics: Aged; Apraxias; Basal Ganglia Diseases; Blood Glucose; Cerebral Cortex; Deoxyglucose; Dominance, Cerebral; Energy Metabolism; Female; Fluorodeoxyglucose F18; Humans; Male; Muscle Rigidity; Nerve Degeneration; Neurologic Examination; Parkinson Disease, Secondary; Pyramidal Tracts; Tomography, Emission-Computed; Tremor | 1991 |
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Carbidopa; Corpus Striatum; Deoxyglucose; Flunitrazepam; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Macaca fascicularis; Neurons; Organ Specificity; Parkinson Disease; Parkinson Disease, Secondary; Tritium | 1990 |
Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia.
Topics: Animals; Apomorphine; Deoxy Sugars; Deoxyglucose; Dystonia; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary | 1990 |
Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: Animals; Autoradiography; Basal Ganglia; Deoxy Sugars; Deoxyglucose; Energy Metabolism; Female; Image Processing, Computer-Assisted; Macaca fascicularis; Male; MPTP Poisoning; Parkinson Disease, Secondary | 1989 |
PET scanning in dystonia.
Topics: Adult; Aged; Brain; Cerebral Infarction; Deoxyglucose; Dystonia; Fluorodeoxyglucose F18; Glucose; Humans; Middle Aged; Parkinson Disease, Secondary; Reference Values; Tissue Distribution; Tomography, Emission-Computed; Torticollis | 1988 |
Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain Mapping; Deoxy Sugars; Deoxyglucose; Disease Models, Animal; Female; Globus Pallidus; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines; Substantia Nigra | 1986 |
Clinical and acoustical variability in hypokinetic dysarthria.
Topics: Aged; Deoxyglucose; Dysarthria; Fluorine; Fluorodeoxyglucose F18; Glucose; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Phonation; Radioisotopes; Speech; Speech Acoustics; Speech Disorders; Supranuclear Palsy, Progressive; Tomography, Emission-Computed | 1986 |
Changes in the local cerebral metabolic rate for glucose in the MPTP primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Blood Glucose; Deoxyglucose; Energy Metabolism; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines | 1987 |
Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Deoxyglucose; Disease Models, Animal; Female; Glucose; Macaca mulatta; Male; Parkinson Disease, Secondary; Pyridines; Substantia Nigra | 1987 |
Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Brain; Deoxy Sugars; Deoxyglucose; Female; Globus Pallidus; Injections, Intravenous; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines; Synapses; Thalamus | 1985 |
Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cerebral Cortex; Corpus Striatum; Deoxyglucose; Glucose; Macaca fascicularis; Parkinson Disease, Secondary; Pyridines; Substantia Nigra | 1985 |
Stress-induced neurological impairments in an animal model of parkinsonism.
Topics: Animals; Bupropion; Corpus Striatum; Deoxyglucose; Desipramine; Dopamine; Dose-Response Relationship, Drug; Hydroxydopamines; Injections, Intraventricular; Male; Neural Pathways; Norepinephrine; Oxidopamine; Pargyline; Parkinson Disease, Secondary; Propiophenones; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stress, Physiological | 1985 |